From Bench to Bedside: Novel Strategies Addressing the Negative Symptoms of Schizophrenia to Improve Clinical and Functional Outcomes

CMEO Snack

Premiere Date: Wednesday, July 24, 2019

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date: Thursday, December 31, 2020

Begin Activity Now


John Lauriello, MD John Lauriello, MD (Moderator)
Chair, Department of Psychiatry and Human Behavior
Sidney Kimmel Medical College at Thomas Jefferson University
Jefferson Enterprise Senior Vice President for Behavioral Health
Philadelphia, PA

Christoph U. Correll, MD Christoph U. Correll, MD 
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Statement of Need

Schizophrenia is a chronic and debilitating disease, and pharmacotherapy for it has focused on the management of positive symptoms using atypical antipsychotics, leading to negative symptoms that contributed more to impaired quality of life being left untreated or underrated. Due to the persistent and chronic nature of negative symptoms, the need for effective therapy with a novel mechanism of action (MOA) is paramount.

This CME Outfitters Snack features expert faculty examining the impact on negative symptoms in remission and recovery, evaluating clinical trial updates on novel therapies with unique MOAs, and integrating pharmacologic knowledge of D3 receptor function as it pertains to treatment selection for the negative symptoms of schizophrenia.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Examine the clinical implications of negative symptoms of schizophrenia on recovery and restoration of function.
  • Evaluate clinical trial updates on novel therapies with unique mechanisms of action (MOAs) that address the negative symptoms of schizophrenia.
  • Integrate pharmacologic knowledge of D3 receptor function into individualized treatment selection for the negative symptoms of schizophrenia.

Financial Support

Supported by an educational grant from Allergan.

Target Audience

Psychiatrists, primary care physicians, physician assistants, and nurse practitioners who treat patients with schizophrenia.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP Credit (American Association of Nurse Practitioners):
This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043697. This activity was planned in accordance with AANP Accreditation Standards and Policies.

AAPA Credit (American Academy of PA's):
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 05/24/2019. PAs should only claim credit commensurate with the extent of their participation.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Lauriello reports that he receives grants from Alkermes - Event Monitoring Board - Grant to the University of Missouri, Feb. 2017. He receives research support from Clinical research site - Florida Atlantic University Grant funded by Otsuka America Pharmaceutical, Inc. He is on the Alkermes Advisory Board (Nov. 2017). He receives other financial or material support from Alkermes - Co-author American Society of Psychopharmacology Poster.

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceutical, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Alkermes; Allergan; Angelini Pharma Inc.; Boehringer-Ingelheim; Gedeon Richter; Gerson Lehrman Group, Inc.; Indivior; IntraCellular Therapies; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase, Inc.; Neurocrine Biosciences, Inc.; Novel Pharmaceuticals, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovian Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceutical Industries Ltd. He is a stock shareholder (directly purchased) of Janssen Pharmaceutical, Inc.; and Otsuka America Pharmaceutical, Inc. He provides expert testimony for Bristol-Myers Squibb Company. He is a Data Safety Monitoring Board Member/Chair for Boehringer-Ingelheim; Lundbeck; Rovi; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

This document was last modified on: